Dr. Rohit Jain on factors affecting treatment selection in renal cell carcinoma

Rohit Jain, MD, Moffitt Cancer Center, discusses risk status and other factors he considers in treatment selection for patients with advanced renal cell carcinoma (RCC).

Note: this interview was filmed before the FDA approval of pembrolizumab plus lenvatinib for the first-line treatment of adult patients with advanced RCC.

Related Videos
hospital corridor
Andrew Wood, MD, answers a question during a Zoom interview
hospital hallway
Illustration of kidney cancer
Laura Bukavina, MD, MPH, and Sarah P. Psutka, MD, MS, are interviewed on Zoom by Ben Saylor from Urology Times
Cross section of human kidney
Related Content
© 2023 MJH Life Sciences

All rights reserved.